Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus

Journal of Rheumatology

Volumn 35, Issue 7, 2008, Pages 1307-1313

  Kuryliszyn Moskal, Anna ^a   Klimiuk, Piotr Adrian ^a   Ciolkiewicz, Mariusz ^a   Sierakowski, Stanislaw ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

E selectin; Endothelial activation markers; Endothelin 1; Systemic lupus erythematosus; Thrombomodulin

Indexed keywords

CELL MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; THROMBOMODULIN;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR ENDOTHELIUM;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; E-SELECTIN; ENDOTHELIAL CELLS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; THROMBOMODULIN;

EID: 47349107741     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 2004;3:423-53.
2. Bujan S, Ordi-Ros J, Paredes J, et al. Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann Rheum Dis 2003;62:859-65.
3. Breedveld FC. Vasculitis associated with connective tissue disease. Baillieres Clin Rheumatol 1997;11:315-34.
4. Hurrairah H, Ferro A. The role of endothelium in the control of vascular function. Int J Clin Pract 2004;58:173-83.
5. Krishnaswamy G, Kelley J, Yerra L, Kelly-Smith J, Chi DS. Human endothelium as a source of multifunctional cytokine: Molecular regulation and possible role in human disease. J Interferon Cytokine Res 1999;19:91-104.
6. Clavel G, Bessis N, Boissier MC. Recent data on the role for angiogenesis in rheumatoid arthritis. Joint Bone Spine 2003;70:321-6.
7. Ballara S, Taylor PC, Reusch P, Marme D, Maini RN, Paleolog E. Serum vascular endothelial growth factor (VEGF) and soluble VEGF receptor in inflammatory arthritis. Arthritis Rheum 2001:44:2055-64.
8. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciolkiewicz M. Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities. Arch Immunol Ther Exp 2007;55:179-85.
9. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciolkiewicz M. A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clin Rheumatol 2006;25:314-9.
10. Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998;139:1049-51.
11. Navarro C, Candia-Zuniga L, Silveira LH, et al. Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Lupus 2002;11:21-4.
12. Moreli S, Ferri C, Polettini E, et al. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 1995;99:255-60.
13. Yoshio T, Masuyama J, Mimowi A, Takeda A, Minota S, Kano S. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis 1995;54:361-5.
14. Haq A, El-Ramahi K, Al-Dalaan A, Al-Sedairy ST. Serum and synovial fluid concentrations of endothelin-1 in patients with rheumatoid arthritis. J Med 1999;3:51-60.
15. Boehme MW, Schmitt WH, Youinou P, Stremmel WR, Gross WL. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med 1996;101:387-94.
16. Witte T, Hartung K, Sachse C, et al. Thrombomodulin in systemic lupus erythematosus: association with clinical and laboratory parameters. Rheumatol Int 1999;19:15-8.
17. Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease. Am J Hypertens 2001;14:44S-54S.
18. Coll-Vinent B, Cebrian M, Cid MC, et al. Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis Rheum 1998;41:435-44.
19. Kevil CG, Bullard DC. Roles of leukocyte/endothelial cell adhesion molecules in the pathogenesis of vasculitis. Am J Med 1999;106:677-87.
20. Yamane K, Ihn H, Kubo M, et al. Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with localized scleroderma. J Am Acad Dermatol 2000;42:64-99.
21. Smith CW. Potential significance of circulating E-selectin. Circulation 1997;95:1986-8.
22. Nyberg F, Stephansson E. Elevated soluble E-selectin in cutaneous lupus erythematosus. Adv Exp Med Biol 1999;455:153-9.
23. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10:413-45.
24. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
25. Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91.
26. Calamia KT, Balabanova M. Vasculitis in systemic lupus erythematosus. Clin Dermatol 2004;22:148-56.
27. Kelly JJ, Whitworth JA. Endothelin-1 as a mediator in cardiovascular disease. Clin Exp Pharmacol Physiol 1999;26:158-61.
28. Goldie GR. Endothelins in health and disease: an overview. Clin Exp Pharmacol Physiol 1999;26:145-8.
29. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 2005;24:111-6.
30. Julkunen H, Saijonmaa O, Gronhagen-Riska C, Teppo AM, Fyhrquist F. Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. Ann Rheum Dis 1991;50:526-7.
31. Robak E, Wozniacka A, Sysa-Jedrzejowska A, Stepien H, Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 2002;11:348-55.
32. Kiraz S, Ertenil I, Benekli M. Clinical significance of hemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. Lupus 1999;8:737-41.
33. Ohdama S, Takano S, Miyake S, Kubota T, Sato K, Aoki N. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases. Am J Clin Pathol 1994;101:109-13.
34. El-Gamal YM, Heshmat NM, El-Kerdany TH, Fawzy AF. Serum thrombomodulin in systemic lupus erythematosus and juvenile idiopathic arthritis. Pediatr Allergy Immunol 2004;15:270-7.
35. Boehme MW, Raeth U, Galle PR, Stremmel W, Scherbaum WA. Serum thrombomodulin - a reliable marker of disease activity in systemic lupus erythematosus: advantage over established serological parameters to indicate disease activity. Clin Exp Immunol 2000;119:189-95.
36. Frijns R, Fijnheer R, Schiel A, Donders R, Sixma J, Derksen R. Persistent increase in plasma thrombomodulin in patients with history of lupus nephritis: endothelial cell activation marker. J Rheumatol 2001;28:514-9.
37. Navarro-Hernandez RE, Oregon-Romero E, Rangel-Villalobos H, et al. sE-Selectin expression and A561C polymorphism in relation to rheumatoid arthritis clinical activity. J Rheumatol 2006;33:1968-72.
38. Klimiuk PA, Sierakowski S, Latosiewicz R, et al. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 2002;61:804-9.
39. Horak P, Scudla V, Hermanovo Z, et al. Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus. Clin Rheumatol 2001;20:337-44.
40. Mrowka C, Sieberth HG. Detection of circulating adhesion molecules ICAM-1, VCAM-1 and E-selectin in Wegener's granulomatosis, systemic lupus erythematosus and chronic renal failure. Clin Nephrol 1995;43:288-96.
41. Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CG. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a longterm prospective study. Clin Exp Immunol 1994;97:439-44.
42. Egerer K, Feist E, Rohr U, Pruss A, Burmester GR, Dorner T. Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 2000;9:614-21.
43. Bruce IN, Gladman DD, Urowitz MB. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000;26:257-78.